Clinical Impact of Staphylococcus aureus Skin and Soft Tissue Infections.
Clinical Impact of Staphylococcus aureus Skin and Soft Tissue Infections.
复制标题
DOI：
10.3390/antibiotics12030557
复制
发表时间：
2023-03-11
影响因子：
4.8
通讯作者：
Parker, Dane
中科院分区：
文献类型：
--
作者：
Linz, Matthew S.;Mattappallil, Arun;Finkel, Diana;Parker, Dane
关键词：
金黄色葡萄球菌是美国皮肤软组织感染(SSTI)中分离出的最常见的病原体。在美国，大多数金黄色葡萄球菌SSTI是由流行克隆USA300引起的。这些感染可能是严重的；2019年，金黄色葡萄球菌的SSTI与全球0.5%的全原因年龄标准化死亡率有关。金黄色葡萄球菌SSTI的临床表现多种多样，从局部症状的浅表感染到单一微生物坏死性筋膜炎，后者可引起全身症状，并可能导致严重并发症或死亡。为了引起皮肤感染，金黄色葡萄球菌使用了一系列毒力因子，包括细胞溶解蛋白、超抗原因子、细胞壁锚定蛋白和用于免疫逃避的分子。对金黄色葡萄球菌SSTIs的免疫反应涉及角质形成细胞和中性粒细胞等初始反应者，这些细胞在感染后得到树突状细胞和T淋巴细胞的支持。金黄色葡萄球菌SSTIS的治疗通常是口服治疗，非肠道治疗保留用于严重症状；范围从头孢菌素和青霉素类药物，如通常用于甲氧西林敏感金黄色葡萄球菌(MSSA)的苯唑西林，到万古霉素(万古霉素)用于甲氧西林耐药金黄色葡萄球菌(MRSA)。治疗挑战包括不良反应，艰难梭菌感染的风险，以及潜在的抗生素耐药性。
The pathogenic bacterium Staphylococcus aureus is the most common pathogen isolated in skin-and-soft-tissue infections (SSTIs) in the United States. Most S. aureus SSTIs are caused by the epidemic clone USA300 in the USA. These infections can be serious; in 2019, SSTIs with S. aureus were associated with an all-cause, age-standardized mortality rate of 0.5 globally. Clinical presentations of S. aureus SSTIs vary from superficial infections with local symptoms to monomicrobial necrotizing fasciitis, which can cause systemic manifestations and may lead to serious complications or death. In order to cause skin infections, S. aureus employs a host of virulence factors including cytolytic proteins, superantigenic factors, cell wall-anchored proteins, and molecules used for immune evasion. The immune response to S. aureus SSTIs involves initial responders such as keratinocytes and neutrophils, which are supported by dendritic cells and T-lymphocytes later during infection. Treatment for S. aureus SSTIs is usually oral therapy, with parenteral therapy reserved for severe presentations; it ranges from cephalosporins and penicillin agents such as oxacillin, which is generally used for methicillin-sensitive S. aureus (MSSA), to vancomycin for methicillin-resistant S. aureus (MRSA). Treatment challenges include adverse effects, risk for Clostridioides difficile infection, and potential for antibiotic resistance.
登录
查看更多内容
氟喹诺酮抗生素和不良事件。
影响因子：
2.7
作者：
Baggio D;Ananda-Rajah MR
通讯作者：
Ananda-Rajah MR
DOI：
10.3390/antibiotics10081020
发表时间：
2021-08-22
期刊：
Antibiotics (Basel, Switzerland)
影响因子：
--
作者：
Chen CY;Chen WC;Lai CC;Shih TP;Tang HJ
通讯作者：
Tang HJ
影响因子：
6.5
作者：
Amagai, M;Yamaguchi, T;Stanley, JR
通讯作者：
Stanley, JR
影响因子：
6.4
作者：
Baggett, HC;Hennessy, TW;Butler, JC
通讯作者：
Butler, JC
影响因子：
3.7
作者：
Zilberberg MD;Chaudhari P;Nathanson BH;Campbell RS;Emons MF;Fiske S;Hays HD;Shorr AF
通讯作者：
Shorr AF